ECTRIMS 2024: New Data Has the Potential to Paving the Way for More Personalised and Effective Treatment Plans
A study presented at ECTRIMS 2024 has identified key biomarkers that can accurately predict disability progression in multiple sclerosis (MS). These findings have the potential to significantly impact MS treatment approaches, enabling the development of more personalized and effective therapeutic strategies tailored to individual patient profiles.
Brænder du for at skrive?
Vil du gerne dele din forskning eller dine kliniske erfaringer med dine kollegaer inden for netop dit speciale? Har du en ide til en artikel, som du gerne vil udgive hos os? Send redaktionen en mail på redaktion@bpno.dk
Send mail til redaktionen